A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants

Phase 1 Completed 35 enrolled Alexion Pharmaceuticals, Inc. Achillion, a wholly owned subsidiary of Alexion · collab

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study was to determine the potential drug interaction between danicopan (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult participants.

Timeline

Start: 2017-04-18
Primary completion: 2017-06-02
Completion: 2017-06-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Danicopan	Small molecule	—	Oral
Subject	Fexofenadine	Unknown	—	Oral
Subject	Midazolam	Small molecule	—	Oral
Subject	Mycophenolate Mofetil	Small molecule	—	Oral

Indications

No indication recorded.